Histopathology Following CCH Injection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04236635 |
Recruitment Status :
Completed
First Posted : January 22, 2020
Last Update Posted : November 13, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Characteristics of Subcutaneous Tissue | Drug: EN3835 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 10 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | A Phase 2B, Open-Label Study to Explore Tissue Histopathology Following Subcutaneous Injection of Collagenase Clostridium Histolyticum Using An Abdominoplasty Model |
Actual Study Start Date : | December 20, 2019 |
Actual Primary Completion Date : | September 23, 2020 |
Actual Study Completion Date : | October 26, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Single CCH Subcutaneous Injection Technique
Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.
|
Drug: EN3835
Collagenase Clostridium Histolyticum (CCH) |
Experimental: Multiple CCH Subcutaneous Injection Technique
Approximately 0.07mg EN3835 (Collagenase Clostridium Histolyticum) in each injection.
|
Drug: EN3835
Collagenase Clostridium Histolyticum (CCH) |
- Histopathology before and after CCH treatment compared to control tissue (tissue not administered with CCH) [ Time Frame: Approximately 3 months ]Histopathology of removed tissue defined by the observation and analysis of the removed specimen by a trained Pathologist

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Be adequately informed and understand the nature and risks of the study and be able to provide consent.
- Be undergoing planned elective abdominoplasty.
- Be willing to have their tissue donated for evaluation.
- Be judged to be in good health.
- Have a negative pregnancy test.
- Be willing and able to cooperate with the requirements of the study.
Exclusion Criteria:
- Is from a vulnerable population, as defined by the US Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full time, etc) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
- Has systemic conditions (coagulation disorders, malignancy, keloidal scar, abnormal wound healing) that restricts study participation.
- Has local (in the areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study participation.
- Required use of anticoagulant or antiplatelet medication (except ≤ 150 mg aspirin daily) before or during participation in the trial.
- Past history of any abdominal surgery, including but not limited to: liposuction, caesarean section, appendectomy, cholecystectomy, or umbilical hernia repair.
- Has used or intends to use any local applications/therapies/injections/procedures that restricts study participation.
- Is presently nursing or providing breast milk in any manner.
- Intends to become pregnant during the study.
- Intends to initiate an intensive sport or exercise program regimen during the study.
- Intends to use any tanning spray or tanning booths during the study.
- Has received any investigational drug or treatment within 30 days prior to first injection of study drug.
- Has a known systemic allergy to collagenase or any other excipient of study drug.
- Has received any collagenase treatment at any time prior to treatment in this study.
- Any other condition(s) that, in the investigator's opinion, might indicate the subject to be unsuitable for the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04236635
United States, New Jersey | |
Endo Clinical Trial Site #1 | |
Montclair, New Jersey, United States, 07042 | |
United States, New York | |
Endo Clinical Trial Site #2 | |
New York, New York, United States, 10021 |
Study Director: | Karen Chajko | Endo Pharmaceuticals |
Responsible Party: | Endo Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT04236635 |
Other Study ID Numbers: |
EN3835-213 |
First Posted: | January 22, 2020 Key Record Dates |
Last Update Posted: | November 13, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |